Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.20.4
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 01, 2017
USD ($)
Feb. 01, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2005
USD ($)
Nov. 30, 2020
USD ($)
May 31, 2019
USD ($)
Feb. 28, 2019
USD ($)
Nov. 30, 2020
USD ($)
Segment
Unit
shares
Nov. 30, 2019
USD ($)
shares
Dec. 01, 2018
USD ($)
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Number of reportable segments | Segment               3    
Concentration risk related to supplier               The Company depends on one supplier for the source of its collection kits    
Deferred revenue         $ 36,384,360     $ 36,384,360    
Warranty payment $ 100,000 $ 75,000   $ 50,000            
Commission paid               49,609 $ 35,300  
Capitalized contract acquisition costs, net of amortization expense                   $ 329,231
Cumulative amortization expense                   $ 66,533
Additional capitalized contract acquisition costs, net of amortization expense               89,471 87,518  
Impairment of public inventory         1,284,238 $ 2,332,763   1,284,238 2,332,763  
Impairment on long lived assets               0 0  
Uncertain tax provisions         0     0 0  
Provisions for interest or penalties related to uncertain tax positions               0 0  
Advertising cost included in selling, general and administrative expenses               845,454 981,448  
Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings             $ 341,000      
(Loss) gain on marketable securities               (8,000) 28,000  
Loss on cash liquidating distribution               (76,000)    
Investment         $ 807,000     807,000    
Payment warranty       $ 50,000            
Increased payment warranty $ 100,000 $ 75,000                
Stock-based option compensation expense               $ 622,000 $ 398,000  
Employee Stock Incentive Plan [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Number of outstanding options excluded from computation of diluted earnings per share | shares               249,301 70,136  
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Inventory, in units | Unit               6,000    
Number of units, per month | Unit               12    
Maximum [Member] | Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Inventory, in units | Unit               144    
Accounts Receivables [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Period of doubtful for accounts receivable due from client               30 days    
Option One [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Contracted storage amortization period         21 years     21 years    
Option Two [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Contracted storage amortization period         1 year     1 year    
Option Three [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Contracted storage amortization period               lifetime    
Contracted storage amortization description               The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.    
ASC 606 [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]         true     true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date         Dec. 01, 2018     Dec. 01, 2018    
Change In Accounting Principle Accounting Standards Update Transition Option Elected [Extensible List]               us-gaap:AccountingStandardsUpdate201409RetrospectiveMember    
ASU 2016-02 [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]         true     true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date         Dec. 01, 2019     Dec. 01, 2019    
Change In Accounting Principle Accounting Standards Update Transition Option Elected [Extensible List]               us-gaap:AccountingStandardsUpdate201602RetrospectiveMember    
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares     260,000              
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary     $ 1,924,000              
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares     195,000              
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary     $ 3,900              
Saneron [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Ownership interest         33.00%     33.00% 33.00%  
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]                    
Business, Basis of Presentation and Significant Accounting Policies [Line Items]                    
Non-Controlling interest after merger     43.42%